[Correspondence] EXAMINE: targeting risk and treatment in diabetes
Type 2 diabetes mellitus is associated with both microvascular and macrovascular complications. For this reason, the US Food and Drug Administration includes specific requirements for cardiovascular safety assessment before the approval of new anti-diabetic drugs. In 2006, a population-based case-control study1 showed a significantly increased risk of myocardial infarction in patients using glibenclamide. That same year, the ADOPT study2 revealed an increase in the incidence of heart failure with rosiglitazone compared with glibenclamide (hazard ratio [HR] 2·20, 95% CI 1·01–4·79; p=0·05).